Seaport Therapeutics, a pioneering clinical-stage biopharmaceutical company dedicated to transforming neuropsychiatric care, has successfully raised a remarkable $100 million in its latest funding round. This infusion of capital underscores the tremendous support and confidence in Seaport’s innovative approach to addressing significant gaps in neuropsychiatric treatment. With a focus on developing novel medicines that stand out due to their clinical validation and unique mechanisms, the company leverages its proprietary Glyph technology platform, which allows for enhanced oral bioavailability while minimizing common side effects such as hepatotoxicity. The advanced capabilities of the Glyph platform enable Seaport to push boundaries and create first-in-class therapeutics that were previously stalled due to limitations inherent in traditional drug development methods. Spearheaded by a team of industry veterans with extensive experience in neuropsychiatric medicine—including the creators of the promising treatment KarXT—Seaport is poised to make significant strides in this crucial therapeutic area. The newly acquired funds will be instrumental in advancing key candidates within their robust pipeline, all aimed at meeting the urgent needs of patients suffering from various neuropsychiatric conditions. With continued support from an esteemed network of scientists, clinicians, and opinion leaders, Seaport Therapeutics is steadfast in its mission to deliver groundbreaking medicines that can dramatically improve the quality of life for countless individuals. For more information on Seaport’s mission and innovative approach, please visit www.seaporttx.com or follow us on X (formerly Twitter) @SeaportTx.
Seaport Therapeutics Raises $100M in Series A Funding to Advance Neuropsychiatric Medicines: Unlocking Potential with Glyph Technology Platform
Recently funded · $100.0M Series aPharmaceuticals
Get the full Seaport Therapeutics company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
